ערך בספרים למניה: Profusa Inc (PFSA)

Profusa Inc develops unique implantable sensors for long-term metabolite monitoring, establishing a resilient customer base across hospitals and military medicine. On GURU.Markets, the book value per share confirms this correlation, with -206.73 representing the latest metric reading. The defensive nature of the medtech sector ensures that demand for such solutions remains independent of economic cycles.

Scaling the deployment of Lumee biosensors in clinics requires significant capital, making the monitoring of Profusa Inc (PFSA) net assets critically important. Analyzing the book value per common share allows for an assessment of the real assets of Profusa Inc (PFSA) minus all liabilities, filtering out speculative noise and identifying the risk of low resource returns through the capital dynamics shown on this chart.